Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources

Table 2

Phototherapy studies for MF.

Phototherapy	Type of the study	Stage	Response rate, duration of remission	OCEBM
NB-UVB [36]	Prospective	I-IIA	CR in 100% patch vs 60% plaques	Level 3
NB-UVB [41]	Prospective	I	CR in 75%, time to relapse 4.5 m
NB-UVB [40]	Retrospective	I	84%
NB-UVB [51]	Retrospective	I	84% (IA), 78% (IB)
PUVA [46]	Retrospective	I-IIA	CR 63%, 33% maintained remission (84 m), 33% relapsed with DFI (39 m)	Level 2
PUVA [52]	Retrospective	IA-IB	95%, 43 m
PUVA [53]	Prospective	IA-IB	100%, 20 m (IA), 17 m (IB)
PUVA versus NB-UVB [54]	Retrospective	PUVA: IA-IVANB-UVB: IA-IIB	Remission 85% vs 83% time to relapse 10 m vs 11.5 m	Level 2
PUVA versus NB-UVB [55]	Retrospective	I-IIA	Remission: 87.4% vs 94.7% time to relapse: 11.5 m vs. 14.0 m No significant difference
PUVA versus NB-UVB [44]	Meta-analysis	I-IIA	CR in 73.8% vs 62.2% significant difference

OCEBM: Oxford Centre for Evidence-Based Medicine, CR: complete response, DFI: disease-free interval.